Open-Label Study to Evaluate Efficacy and Safety of Ibrexafungerp in Patients With Refractory or Intolerant Fungal Diseases
Invasive Candidiasis, Mucocutaneous Candidiasis, Coccidioidomycosis, Histoplasmosis, Blastomycosis, Chronic Pulmonary Aspergillosis, Allergic Bronchopulmonary Aspergillosis, Invasive Pulmonary Aspergillosis, Recurrent Vulvovaginal Candidiasis, Other Emerging Fungi, Candidiasis, Aspergillosis, Candidiasis, Vulvovaginal, Candidiasis, Invasive, Pulmonary Aspergillosis, Aspergillosis, Allergic Bronchopulmonary, Mycoses, Coccidiosis, Candidiasis, Chronic Mucocutaneous, Ibrexafungerp, Ibrexafungerp (SCY-078)
Lead Scientists at University of California Health
- George Thomposn (ucdavis)
- Peter Chin-Hong, MD (ucsf)
Peter Chin-Hong is Associate Dean for Regional Campuses. He is a medical educator who specializes in treating infectious diseases, particularly infections that develop in patients who have suppressed immune systems, such as solid organ and hematopoietic stem cell transplant recipients. He directs the immunocompromised host infectious diseases program at UCSF.
- accepting new patients
- Start Date
- Completion Date
- Scynexis, Inc.
- Phase 3 research study
- Study Type
- Expecting 200 study participants
- Last Updated